DUBAI, UAE, April 13, 2022 /PRNewswire/ European Wellness Biomedical Group (EW Group), through its Malaysian subsidiary European Wellness Academie, and Dubai- based healthcare distribution
but they never talked about safety. the point i brought up in my presentation was that these are gerks ne therapy products. the fda has a whole section within its laboratory where they research gene therapy including on covid. and they have an advisory committee for gene therapy products. they are not consulting at least publicly their internal people. we want to see those experts in public debate and asked by the committee some probing questions. good news on one hand. oam chron is real tomorrow chron s vaccine efficacy is limited. and boosters are limited. we can t just keep boosting people. and we are waiting for safety
but they never talked about safety. the point i brought up in my presentation was that these are gerks ne therapy products. the fda has a whole section within its laboratory where they research gene therapy including on covid. and they have an advisory committee for gene therapy products. they are not consulting at least publicly their internal people. we want to see those experts in public debate and asked by the committee some probing questions. good news on one hand. oam chron is real tomorrow chron s vaccine efficacy is limited. and boosters are limited. we can t just keep boosting people. and we are waiting for safety
but they never talked about safety. the point i brought up in my presentation was that these are gerks ne therapy products. the fda has a whole section within its laboratory where they research gene therapy including on covid. and they have an advisory committee for gene therapy products. they are not consulting at least publicly their internal people. we want to see those experts in public debate and asked by the committee some probing questions. good news on one hand. oam chron is real tomorrow chron s vaccine efficacy is limited. and boosters are limited. we can t just keep boosting people. and we are waiting for safety
On March 14, 2022, U.S. Food and Drug Administration (FDA) issued two draft guidances: "Human Gene Therapy Products Incorporating Human Genome Editing (GE)"